The Venture Codex

Participated · Seed · Feb 2026

Founded in 2021 out of Princeton University, PolyGone Systems develops patented filtration systems that remove 98% of toxic microplastics from water at 90% lower cost than existing alternatives. Its flagship PolyPod™ units are engineered to treat up to 10 million gallons of water per day, targeting municipal wastewater facilities. Complementing the hardware, the company has launched a microplastics analysis service that provides affordable testing for public agencies, private companies, and utilities to assess contamination and regulatory compliance. PolyGone is currently running a wastewater pilot with the Atlantic County Utilities Authority and has signed three additional commercial deployments slated for 2026 across municipal, industrial, and food-and-beverage customers. Near-term plans include mass production of the PolyPod™ systems and the release of an inline PolyCartridge™ filter for industrial water streams. Management positions the company as a future proprietary data and intelligence provider on microplastic pollution, aiming to become indispensable to water authorities and industrial operators. No revenue figures were disclosed in the articles.

Participated · Seed · Feb 2025

Validose provides an agile dose device platform that pairs a multi-sensor Dose Exoskeleton attachment with real-time data delivery to clinicians and behavioral prompts to drive patient adherence. Its initial commercial product is an ophthalmic smart-dose eye-dropper, with a planned launch in Q2 2025. The platform is designed to support additional form factors, including a CNS-focused nasal spray device and a pill delivery system. Validose also offers a Patient Portal that sends personalized dose reminders, real-time messaging, and behavioral coaching, and a Clinician Dashboard that gives trial coordinators secure, immediate adherence insights. The company emphasizes objective, precise, and secure real-time adherence data to optimize trial outcomes and enable timely interventions. Recent financing will fund final development of the ophthalmic solution.